Business
Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids\r\n \r\n \r\n\r\n\r\nMedical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids\r\n\r\n\r\n\r\n\r\n\r\nSAN DIEGO, CA - January 29, 2026 (NEWMEDIAWIRE) - Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\") today announced a strategic alliance with AXIM Biotechnologies, Inc. (OTC: AXIM) intended to research and develop applications and uses for AXIM's patent for water soluble cannabinoids.\r\nAt the center of the transactions entered into between AXIM and the Company is AXIM's U.S. Patent No. 11,542,226 B2, Polyfunctional Cannabinoids (the \"Patent\"). AXIM assigned to MJNA a fifty percent (50%) right, title, and economic interest in the Patent and all associated intellectual property. The assignment includes rights to:\r\n\r\n Existing and future U.S. and foreign patents and applications\r\n Licensing, enforcement, and monetization proceeds\r\n Claims for past infringement and accrued royalties\r\n \r\n Concurrently, with the Patent assignment, AXIM and MJNA entered into a Consulting Agreement, whereby AXIM will provide the Company with research and development services focused on researching and developing applications and uses for the Patent technology.\r\nIn conjunction with the Patent Assignment and related Consulting Agreement, Dr. Timothy R. Scott, Chairman of the Board and director since 2015, returned as president of MJNA, replacing interim president, Robert A. Wells Jr.  Mr. Wells continues to act as CFO of MJNA.\r\nDr. Scott stated; \"We have tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology. The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA. In addition, MJNA already has significant knowledge and exposure to the cannabinoid market and enjoys relationships in that arena. We think that this alliance is a great fit, with tremendous opportunity for both MJNA and AXIM.\"\r\nCatalina Valeni...